Elizabeth H.Z. Thompson insider trades: Acadia Pharmaceuticals (ACAD) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Elizabeth reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026 | ACAD | ↓ Sell | 16,558 | $26.13 | $433K | Direct | Jul 31, 2026 (1d) |
| Jul 20, 2022 | HZNP | ↓ Sell | 6,007 | $85.00 | $511K | Direct | Jul 20, 2022 (0d) |
| Jul 7, 2022 | HZNP | ↓ Sell | 82 | $85.01 | $7K | Direct | Jul 11, 2022 (4d) |
| Apr 18, 2022 | HZNP | ↓ Sell | 8,098 | $115.64 | $936K | Direct | Apr 20, 2022 (2d) |
| Aug 5, 2021 | HZNP | ↓ Sell | 7,542 | $106.34 | $802K | Direct | Aug 6, 2021 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ACAD insiders
Open-market trades in the last 12 months
About Elizabeth H.Z. Thompson's insider trades
Elizabeth H.Z. Thompson is EVP, Head of Research & Dev at Acadia Pharmaceuticals (ACAD). Since Aug 5, 2021, Elizabeth has reported no open-market purchases and 5 sales worth $2.7M on SEC Form 4. In the last 12 months: 1 sale ($433K).
Their filings also include grants and awards (13 filings), option exercises (4 filings), shares withheld for taxes (3 filings), shares returned to the company (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ACAD insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.